Concluding Remarks


Click here to start

Table of Contents

Concluding Remarks

Consistency of Efficacy Results with UFT/LV Treatment

Updated Survival

5-FU/LV vs. 5-FU (or vs. UFT/LV) Randomized Trials in Metastatic Colorectal Cancer

Median Relative Dose Intensity 5-FU

Consistency of Safety Results (I)

Consistency of Safety Results (II)


Proposed Indication

Recommended Dosage

Author: Bristol-Myers Squibb Pharmaceutical Research Institute